产品详情
| 中文名称:莫匹拉韦 | 英文名称:Molnupiravir |
| CAS:1686124-74-2 | 纯度规格: 99 |
| 产品类别: 中间体 |
2024-04-30
莫匹拉韦
Molnupiravir
1g m/RMB
99
中间体
Molnupiravir EIDD-2801是一种高效的核糖核苷类似物的口服生物可利用形式，可抑制多种RNA病毒的复制，包括SARS-CoV-2。
EIDD-2801 是核糖核苷类似物 EIDD-1931 的口服生物可利用的异丙酯前药。EIDD-2801 显示出广泛的抗流感病毒 (influenza virus) 和冠状病毒 (coronaviruses) 的活性，如 SARS-CoV-2，MERS-CoV，SARS-CoV。EIDD-2801 有用于 COVID-19 和季节性，流行性流感的潜力。
EIDD-2801可抑制多种RNA病毒的复制，包括SARS-CoV-2（COVID-19的致病因子），通过两种不同冠状病毒（SARS-CoV1和MERS）的动物研究，证明EIDD-2801可以改善肺功能、减少体重减轻并减少肺中的病毒量。除了针对冠状病毒的活性外，在实验室研究中，EIDD-2801还显示出针对季节性流感、呼吸道合胞病毒、基孔肯雅病毒、埃博拉病毒、委内瑞拉马脑炎病毒和东部马脑炎病毒的活性。
Molnupiravir ;EIDD-2801 is an orally bioavailable form of a highly potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. EIDD-2801 has been shown to improve pulmonary function, decrease body weight loss and reduce the amount of virus in the lung. In addition to activity against coronaviruses, EIDD-2801, in laboratory studies, has demonstrated activity against seasonal and bird influenza, respiratory syncytial virus, chikungunya virus, Ebola virus, Venezuelan equine encephalitis virus, and Eastern equine encephalitis virus. EIDD-2801 is a prodrug of EIDD-1931.
关键字： EIDD-2801EIDD2801;MK4482);莫纳匹拉韦;
公司简介
ANHUI HAIKANG PHARMACEUTICAL CO.,LTD. was established in 2009 in Anqing City, Anhui Province. It is located along the north bank of mid and lower reaches of the Yangtze River. Enjoying favorable? geographic superiorities and convenient transportation infrastructure: such as highway, high speed railway, airport, inland shipping container terminal and so on. By plane, it takes just 1 hour to Shanghai, 2 hours to Guangzhou or Beijing; by high speed train it takes 2 hours to reach Nanjing, 4 hours to Shanghai, 6.5 hours Beijing.Since founded the company has been committed to the production, sales
| 成立日期 |
2009-11-02
（15年）
|
注册资本 |
贰仟贰佰伍拾万圆整
|
| 员工人数 |
10-50人 |
年营业额 |
￥ 100万-300万 |
| 主营行业 |
医药中间体,其他中间体,原料药,呼吸系统用药,其他抗感染类 |
经营模式 |
工厂,定制 |